The Silent Signal: AI Listens as You Sleep to Predict Asthma Attacks

OXFORD, England – September 14, 2026 – For millions living with asthma, the night can be a source of anxiety, a time when symptoms like coughing can signal worsening control over their condition. The challenge has always been capturing these signals reliably. A groundbreaking new study, however, suggests a future where the simple act of sleeping provides all the data needed for early intervention, thanks to artificial intelligence that listens.

At the European Respiratory Society (ERS) Congress 2026, UK-based Albus Health unveiled findings from a study with Leiden University Medical Centre that could fundamentally alter the management of chronic respiratory disease. The research demonstrated a powerful, statistically significant link between nocturnal cough, measured passively by a contactless bedside device, and the subsequent severity of a patient's asthma symptoms. This innovation doesn't just offer a new data point; it represents a paradigm shift from subjective patient memory to objective, continuous monitoring, moving healthcare from a reactive to a proactive stance.

A Breakthrough in Objective Monitoring

The long-standing challenge in clinical trials and daily patient care is the reliance on patient-reported outcomes. Remembering the frequency of nighttime awakenings or the intensity of a cough from the previous day is notoriously unreliable. The Leiden study, presented at ERS, directly addresses this problem.

Researchers followed adults with severe, uncontrolled asthma, using the Albus Home contactless system to monitor their nocturnal cough patterns for up to a year. The results were striking: for every five-fold increase in the rate of coughing during the night, the odds of the patient reporting a worse asthma symptom score the following day were more than 1.5 times higher. This predictive association didn't just apply to the next day; it persisted for up to three days, offering a crucial window for potential intervention.

What makes this finding particularly potent is the method of data collection. Participants simply placed the device at their bedside. There were no wearables to attach, no buttons to press, and no diaries to fill out. The result was near-perfect adherence, with participants being monitored for a median of 9.5 hours per night for nearly the entire year. The only significant gaps in data occurred when patients were away from home—a testament to the system's unobtrusive nature.

"Nocturnal symptoms are an important and burdensome feature of asthma, yet they are difficult to monitor reliably over long periods," said Fleur Meulmeester, the study's lead author from Leiden University Medical Centre. "Showing that objective nocturnal cough data correlate with patient-reported symptoms highlights the potential of passive monitoring to provide valuable insights into asthma management."

The Technology Behind the Signal

The Albus Home system is a prime example of the burgeoning field of ambient health monitoring. It operates on a sophisticated blend of proprietary acoustic analysis and machine learning algorithms. Placed in a patient's room, the device continuously listens for respiratory events, using its AI to distinguish a cough from a sneeze or a snore with high accuracy. It then quantifies these events, turning ambient sound into a powerful digital biomarker.

This approach stands in stark contrast to other forms of remote patient monitoring. Smart inhalers, while valuable for tracking medication use, still require active patient engagement. Wearable sensors, such as patches or smart shirts, can provide continuous data on vital signs but often face adherence challenges due to comfort issues or the need for regular charging and application. The Albus Health platform bypasses these hurdles entirely.

"The ability to gather objective data without asking the patient to do anything is the holy grail of chronic disease management," noted one digital health analyst. By removing the burden from the patient, the technology ensures a consistent, high-fidelity data stream that was previously unattainable outside of a sleep lab.

The company is already looking ahead. The press release noted that its latest-generation platform is designed to capture an even broader array of physiological and environmental data, promising deeper insights into the complex interplay of factors that influence disease activity.

Reshaping Asthma Care and Patient Lives

The implications for clinical practice are profound. For physicians, the objective cough data serves as an early warning system. Instead of waiting for a patient to report a severe exacerbation, a doctor could be alerted to a rising cough frequency and proactively adjust medication or schedule a telehealth consultation. This aligns perfectly with modern asthma management guidelines, like those from the Global Initiative for Asthma (GINA), which emphasize controlling symptoms and reducing future risk.

This data-driven approach also paves the way for truly personalized medicine. By analyzing an individual's cough patterns over time, clinicians can identify unique triggers, assess treatment effectiveness with greater precision, and tailor care plans to a patient's specific phenotype. The study's observation that individual cough patterns varied widely underscores the need for such personalization.

Perhaps most importantly, this technology promises to improve the quality of life for patients. It reduces the mental load and anxiety associated with constant self-monitoring. Knowing that a silent guardian is tracking a key symptom can provide peace of mind, while the objective data can foster more productive and informed conversations with healthcare providers, empowering patients to take a more active role in their care.

A New Gold Standard for Drug Development

The impact of this technology extends far beyond the clinic and into the world of pharmaceutical research. Developing new drugs for respiratory conditions is a multi-billion-dollar endeavor, and clinical trials have long been hampered by their reliance on subjective endpoints. Objective, quantifiable data from a system like Albus Home provides a much more robust measure of a drug's efficacy.

This is why, as the company claims, multiple top-10 pharmaceutical companies are already using the platform. For them, it de-risks clinical trials by providing higher-quality evidence, potentially identifying treatment responders earlier and with greater certainty. By reducing patient burden, the technology also helps improve trial adherence and reduce costly dropout rates.

This fits into the larger industry trend of leveraging Real-World Evidence (RWE) to supplement traditional trial data. The continuous, longitudinal data gathered in a patient's natural home environment is exactly the kind of RWE that regulators and payers are increasingly demanding to see.

Backed by prominent investors like Octopus Ventures, Albus Health is positioning itself not just as a device maker, but as a pivotal data-analytics company at the intersection of AI, operations, and strategic growth. In a rapidly expanding remote patient monitoring market, its focus on a specific, high-value digital biomarker provides a clear competitive edge. The findings from the ERS Congress are more than just a promising study; they are a clear signal that the future of chronic disease management is one where technology works silently in the background, listening for the clues that help us live healthier lives.